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Abstract
Targeted genome editing using engineered nucleases has rapidly transformed from a niche 
technology to a mainstream method used by many biological researchers. This widespread 
adoption has been largely fueled by the emergence of the clustered regularly interspaced short 
palindromic repeat (CRISPR) technology, an important new platform for generating RNA-guided 
nucleases (RGNs), such as Cas9, with customizable specificities. RGN-mediated genome editing 
is facile, rapid and has enabled the efficient modification of endogenous genes in a wide variety of 
biomedically important cell types and novel organisms that have traditionally been challenging to 
manipulate genetically. Furthermore, a modified version of the CRISPR-Cas9 system has been 
developed to recruit heterologous domains that can regulate endogenous gene expression or label 
specific genomic loci in living cells. Although the genome-wide specificities of CRISPR-Cas9 
systems remain to be fully defined, the capabilities of these systems to perform targeted, highly 
efficient alterations of genome sequence and gene expression will undoubtedly transform 
biological research and spur the development of novel molecular therapeutics for human disease.
The capability to introduce targeted genomic sequence changes into living cells and 
organisms provides a powerful tool for biological research as well as a potential avenue for 
therapy of genetic diseases. Frameshift knockout mutations enable reverse genetics and 
assignment of function, sequence insertions can be used to fuse genes to epitope tags or 
other functional domains, such as fluorescent proteins to endogenous gene products, and 
specific sequence alterations can be used to induce amino acid substitutions for disease 
modeling, to transfer traits in agricultural crops and livestock, and to correct defective genes 
for therapeutic applications. For many years, strategies for efficiently inducing precise, 
targeted genome alterations were limited only to certain organisms (for example, using 
homologous recombination in yeast or recombineering in mice) and often required drug-
selectable markers or left behind ‘scar’ sequences associated with the modification method 
(for example, residual loxP sites from Cre recombinase-mediated excision). Targeted 
genome editing using customized nucleases provides a new, general method for inducing 
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targeted deletions, insertions and precise sequence changes in a broad range of organisms 
and cell types. The high efficiency of genome editing obviates the need for additional 
sequences, such as drug-resistance marker genes, and therefore the need for additional 
manipulations to remove them.
A crucial first step for performing targeted genome editing is the creation of a DNA double-
stranded break (DSB) at the genomic locus to be modified1. Nuclease-induced DSBs can be 
repaired by one of at least two different pathways that are operative in nearly all cell types 
and organisms: non-homologous end-joining (NHEJ) and homology-directed repair (HDR) 
(Fig. 1). NHEJ can lead to the efficient introduction of insertion/deletion mutations (indels) 
of various lengths, which can disrupt the translational reading frame of a coding sequence or 
the binding sites of trans-acting factors in promoters or enhancers. HDR-mediated repair can 
be used to introduce specific point mutations or to insert desired sequences through 
recombination of the target locus with exogenously supplied DNA ‘donor templates’. When 
targeted nuclease-induced DSBs are used, the frequencies of these alterations are typically 
higher than 1% and, in some cases, can be 50% or higher; modifications at these levels 
enable identification of desired mutations by simple screening, without the need for drug 
resistance marker selection.
Early methods for targeting DSB-inducing nucleases to specific genomic sites relied on 
protein-based systems with customizable DNA-binding specificities such as meganucleases, 
zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). 
These platforms have enabled important advances, but each has its own set of associated 
advantages and challenges (Box 1). More recently, a novel platform based on a bacterial 
CRISPR-Cas system has been developed that is unique and flexible due to its dependence on 
RNA as the moiety that targets the nuclease to a desired DNA sequence. In contrast to ZFN 
and TALEN platforms that use protein–DNA interactions for targeting, these RGNs use 
simple base pairing rules between an engineered RNA and the target DNA site.
In this review, we describe how this RNA-guided system works and how it has been applied 
to perform genome editing across a wide variety of cell types and whole organisms. We also 
discuss advantages and limitations of this system, including assessment of off-target effects 
and recent strategies for improving specificity, and how it can be re-purposed for other 
applications such as regulation of gene expression and selective labeling of the genome. 
Finally, we consider the next set of challenges that will need to be addressed for this 
emerging genome editing platform.
From bacterial CRISPR-Cas immune system to engineered RNA-guided 
nucleases
CRISPR systems are adaptable immune mechanisms used by many bacteria to protect 
themselves from foreign nucleic acids, such as viruses or plasmids2-5. The type II CRISPR 
system incorporates sequences from invading DNA between CRISPR repeat sequences 
encoded as arrays within the host genome (Fig. 2a). Transcripts from the CRISPR repeat 
arrays are processed into CRISPR RNAs (crRNAs) each harboring a variable sequence 
transcribed from the invading DNA, known as the “protospacer” sequence, as well as part of 
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the CRISPR repeat. Each crRNA hybridizes with a second transactivating CRISPR RNA 
(tracrRNA) and these two RNAs complex with the Cas9 nuclease6. The protospacer-
encoded portion of the crRNA directs Cas9 to cleave complementary target DNA sequences, 
if they are adjacent to short sequences known as “protospacer adjacent motifs” (PAMs). 
Protospacer sequences incorporated into the CRISPR locus are not cleaved because they are 
not present next to a PAM sequence.
The type II CRISPR system from Streptococcus pyogenes has been adapted for inducing 
sequence-specific DSBs and targeted genome editing7. In its simplest and most widely used 
form, two components must be introduced and/or expressed in cells or an organism to 
perform genome editing: the Cas9 nuclease; and a ‘guide RNA’ (gRNA), consisting of a 
fusion of a crRNA and a constant tracrRNA (Fig. 2b). 20 nucleotides at the 5′ end of the 
gRNA (corresponding to the protospacer sequence of the crRNA; Fig. 2c) direct Cas9 to a 
specific target DNA site using standard RNA-DNA complementarity base pairing rules. 
These target sites must lie immediately 5′ of a PAM sequence that matches the canonical 
form 5′-NGG (although recognition at sites with alternate PAM sequences (e.g. 5′-NAG) 
has also been reported, albeit at less efficient rates7-9). Thus, with this system, Cas9 nuclease 
activity can be directed to any DNA sequence of the form N20-NGG simply by altering the 
first 20 nts of the gRNA to correspond to the target DNA sequence. Type II CRISPR 
systems from other species of bacteria that recognize alternative PAM sequences and that 
utilize different crRNA and tracrRNA sequences have also been used to perform targeted 
genome editing10-12. However, because the most commonly used and extensively 
characterized system to date is based on the S. pyogenes system, the remainder of this 
review focuses on this particular platform and its components unless otherwise noted.
Following the initial demonstrations in 2012 that Cas9 could be programmed to cut various 
DNA sites in vitro7, a flurry of papers published in 2013 showed that this platform also 
functions efficiently in a variety of cells and organisms. Initial proof-of-principle studies 
showed that Cas9 could be targeted to endogenous genes in bacteria8, cultured transformed 
human cancer cell lines and human pluripotent stem cells in culture13-16, as well as in a 
whole organism, the zebrafish17. Subsequently, Cas9 has been used to alter genes in yeast18, 
tobacco19, 20, thale cress19, rice21, 22, wheat21, sorghum23, mice24, 25, rats26, rabbits27, 
frog28, fruit flies29, 30 silkworm31,and roundworms32 (see Table 1 for a list of these 
published reports).Cas9-induced DSBs have been used to introduce NHEJ-mediated indel 
mutations as well as to stimulate HDR with both double-stranded plasmid DNA and single-
stranded oligonucleotide donor templates. The capability to introduce DSBs at multiple sites 
in parallel using the Cas9 system is a unique advantage of this platform relative to 
meganucleases, ZFNs, or TALENs. For example, expression of Cas9 and multiple gRNAs 
has been used to induce small and large deletions or inversions between the DSBs14,33-35, to 
simultaneously introduce mutations in three genes in rat cells36, five genes in mouse ES cell 
clones24 and five genes in the somatic cells of a single zebrafish37.
The simplicity of Cas9 targeting has also inspired the generation of large gRNA libraries 
using array-based oligonucleotide synthesis. These libraries can be engineered to encompass 
multiple gRNAs for every target gene in a host organism, thereby greatly facilitating 
forward genetic screens and selections. In contrast to short hairpin RNA libraries, which 
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only mediate gene knockdown, these gRNA libraries have been used with Cas9 nuclease to 
generate knockout mutations. Libraries comprised of between ~64,000 and ~87,000 distinct 
gRNAs have been used to demonstrate the capacity for positive and negative forward 
genetic phenotype screens in both human and mouse cells38-40.
Variant Cas9 nickases that cut one strand, rather than both strands, of the target DNA site 
have also been shown to be useful for genome editing. Introduction of a D10A or H840A 
mutation into the RuvC1- or HNH-like nuclease domains present in Cas9 (Fig. 3a)41, 42 
results in the generation of nickases that cut either the complementary or non-
complementary DNA target strands, respectively, in vitro7, 12, 43 (Fig. 3b and 3c). 
Consistent with previous studies performed with ZFN-derived nickases44-46, Cas9 nickases 
can, at some sites, induce HDR with reduced levels of concomitant NHEJ-mediated 
indels13, 14. However, although at some sites Cas9 nickase can induce HDR with 
efficiencies similar to what is observed with the Cas9 nuclease from which it is derived13, 14, 
these rates can also be greatly reduced at other sites47, 48. Importantly, the frequencies of 
indel mutations introduced by nickases has also been reported to be high at certain 
sites13, 47-49. Although the precise DNA repair pathways by which these various alterations 
are induced remain as yet undefined, one potential mechanism that has been postulated is 
that passage of a replication fork through a nuclease-induced nick site might result in a DNA 
DSB. Additional studies with Cas9 nickases will be needed to better understand locus-
dependent differences in the efficiencies of HDR and indel mutation induction.
Determining the specificities of RNA-guided Cas9 nucleases
Although RGNs generally cleave their intended target sites reliably, an important question is 
to what extent these nucleases induce off-target cleavage events (and therefore unwanted 
NHEJ-induced indel mutations). To assess RGN specificity, several groups have created 
variant gRNAs bearing one to four nucleotide mismatches in the complementarity region 
and then examined the abilities of these molecules to direct Cas9 nuclease activity in human 
cells at reporter gene50 or endogenous gene14, 51 target sites. These studies showed that 
mismatches are generally better tolerated at the 5′ end of the 20 nt targeting region of the 
gRNA than at the 3′ end; this result is consistent with previous experiments performed in 
vitro and in bacterial cells, which suggested that the 8 – 12 bps at the 3′ end of the targeting 
sequence (a.k.a. the seed sequence) are crucial for target recognition7, 8, 14, 52, 53. However, 
the effects of single and double mismatches are not always predictable based on their 
location within the gRNA targeting region; some mismatches in the 5′ end can have 
dramatic effects whereas some in the 3′ end do not significantly affect Cas9 activity50. In 
addition, not all nucleotide substitutions at a given position necessarily have equivalent 
effects on activity51.
A reciprocal, and perhaps more relevant, approach for studying specificity is to assess the 
activities of Cas9 at potential off-target genomic DNA target sites, (i.e. sites that have a few 
nucleotide differences compared to the intended target). A number of studies have 
examinedpotential off-target sites that differ at one to six positions from the on-target site in 
human cells47, 48, 50, 51, 54. Collectively, these reports have found cases of off-target 
mutations at sites that differ by as many as five positions within the protospacer region50 
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and/or that have an alternative PAM sequence of the form NAG51. Interestingly, indel 
mutation frequencies at these off-target sites can be high enough (>2-5%) to detect using the 
relatively insensitive T7 Endonuclease I (T7E1) mutation mismatch assay and to sometimes 
be comparable to the on-target site mutation frequency48, 50. In addition, more sensitive 
deep sequencing assays have been used to identify lower frequency off-target 
mutations48, 55, 56. It is important to note that all of these directed studies only examined a 
subset of the much larger number of potential off-target sites in the genome. For example, 
any given 20 nt protospacer will have typically have hundreds to thousands of potential off-
target sites that differ at four or five positions, respectively, in 6 × 109 bps of random DNA. 
In addition, although it has been suggested that higher GC content at the RNA:DNA 
hybridization interface might potentially help to stabilize Cas9:gRNA complexes, high rates 
of mutagenesis have been observed for off-target sites with as little as 30% matched GC-
content9, 50.
A somewhat more comprehensive strategy for examining Cas9 specificities is to identify 
off-target sites from a partially degenerate library of variants that is based on the intended 
on-target sequence. One recent report identified sites from such libraries based on their 
abilities to be bound by a catalytically inactive form of Cas9 fused to a transcriptional 
activation domain (see further discussion below)49. This study found sites that were 
mismatched by as many as three (and possibly more) positions relative to the on-target 
site49. These results are similar to those of another study, which used in vitro selection for 
Cas9 nuclease cleavage activity to identify potential off-target sites from a partially 
degenerate library of target site variants. Some of the off-target sites identified by these in 
vitro selections (with up to four mismatches) were also shown to be mutated in human 
cells9.
A recent study using whole exome sequencing did not find evidence of Cas9-induced off-
target mutations in three modified human K562 cell line clones57. Although the authors 
acknowledge that the high false negative result rate associated with exome sequencing 
analysis limits interpretation of this data, these results do suggest that with careful target 
selection it may be possible to isolate Cas9-edited cells with otherwise intact exomes. 
Additional examples with deeper sequencing coverage and whole genome (rather than 
whole exome) sequencing will be needed to determine how readily cells that do not have 
off-target mutations can be isolated. The ability to do so would encourage broader research 
application of Cas9 technology. However, it is worth noting that deep sequencing the 
genomes of individual cell clones is neither a sensitive nor an effective approach for 
defining the full genomewide spectrum of Cas9 off-target sites.
Overall, the various studies published to date strongly suggest that off-target sites of RNA-
guided Cas9 nucleases can be variable in frequency and challenging to predict. For any 
given target site, it is not currently possible to predict how many mismatches can be 
tolerated, nor do we fully understand why some sites are cleaved whereas other are not. We 
also do not know how genomic and/or epigenomic context might affect the frequency of 
cleavage. Although some initial evidence suggests that DNA methylation may not inhibit 
Cas9-based genome editing55, it seems both plausible and likely that chromatin structure 
could play a role in off-target site accessibility. A more comprehensive understanding of 
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Cas9 off-target effects will have to await the development of unbiased, global measures of 
Cas9 specificity in cells
Methods for reducing off-target effects of Cas9 nucleases
Even with an incomplete understanding of RNA-guided Cas9 nuclease specificity, 
researchers have begun to explore various approaches to reduce off-target mutagenic effects. 
One potential strategy is to test the effects of reducing the concentrations of gRNA and/or 
Cas9 expressed in human cells. Results with this approach have been mixed with one group 
observing proportionately larger decreases in rates of off-target mutagenesis relative to on-
target mutagenesis for two gRNAs51 and another group observing nearly proportionate 
decreases for two other gRNAs50. The use of modified gRNA architectures with truncated 3′ 
ends (within the tracrRNA-derived sequence) or with two extra guanine nucleotides 
appended to the 5′ end (just prior to the complementarity region) also yielded better on-
target to off-target ratios but again with considerably lower absolute efficiencies of on-target 
genome editing57, 58.
Another proposed approach for improving specificity involves the use of “paired nickases” 
in which adjacent off-set nicks are generated at the target site using two gRNAs and Cas9 
nickase47, 49, 57(Fig. 3d), a strategy analogous to one originally performed with pairs of 
engineered zinc finger nickases46. Cas9 nickases targeted to sites on opposite DNA strands 
separated by four to 100 bps can efficiently induce indel mutations or HDR events with a 
single-stranded DNA oligonucleotide donor template in human and mouse cells47, 49, 57. It 
has been proposed that the concerted action of paired nickases create a DSB that is then 
repaired by NHEJ or HDR47, 56. Importantly, paired nickases can reduce Cas9-induced off-
target effects of gRNAs in human cells. The addition of a second gRNA and substitution of 
Cas9 nickase for Cas9 nuclease can lead to lower levels of unwanted mutations at previously 
known off-target sites of the first original gRNA47. However, an as-yet unanswered question 
is whether the second gRNA can itself induce its own range of Cas9 nickase-mediated off-
target mutations in the genome. Multiple studies have shown that single Cas9 nickases can 
function on their own to induce indel mutations at certain genomic loci13, 47-49, perhaps 
because an individual nick might be converted to a DSB when a replication fork passes 
through the locus59, 60. Thus, one important way to improve the paired nickase system might 
be to modify it so that the activities of the two gRNAs are strictly co-dependent on each 
other for genome editing activity—that is, so that each gRNA is only active for genome 
editing when bound to DNA in close proximity to the other.
Our group has recently shown that off-target effects can be substantially reduced by using 
gRNAs that have been shortened at the 5′ end of their complementarity regions. These 
truncated gRNAs (tru-gRNAs) bearing 17 or 18 nucleotides of complementarity generally 
function as efficiently as full-length gRNAs in directing on-target Cas9 activity but show 
decreased mutagenic effects at off-target sites and enhanced sensitivity to single or double 
mismatches at the gRNA/DNA interface48. tru-gRNAs are simple to implement and this 
strategy avoids the technical challenges associated with expressing multiple gRNAs in a 
single cell for the paired nickase approach. Importantly, tru-gRNAs might also be used in 
conjunction with other strategies for improving Cas9 specificity (e.g.—tru-gRNAs have 
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already been shown to improve the specificity of paired nickases48) and to improve the 
specificities of dCas9 fusion proteins for non-nuclease applications (described below).
Practical considerations for implementing CRISPR-Cas technology
Due to rapid progress in the field, potential users of CRISPR-Cas technology face a variety 
of choices about how to practice CRISPR-Cas technology. Here we discuss some of the 
parameters to consider when implementing the methodology.
Choice of Guide RNA Platform
It is important to note that the efficiency of Cas9 activity for any given locus can be 
influenced by the architecture of guide RNA(s) used. As described above, most recent 
studies have used a single gRNA that is a fusion of a programmable crRNA and part of the 
tracrRNA, but earlier studies also used a ‘dual gRNA’ configuration in which the crRNA 
and tracrRNA are expressed separately. In general, studies using single gRNAs have 
consistently reported substantially higher editing rates than those using dual 
gRNAs13, 14, 17, 61. These findings suggest that the single gRNA system may be more active 
than the double gRNA system, presumably because two components can assemble more 
efficiently than three components.
In addition, single gRNAs harboring variable lengths of tracrRNA sequence on their 3′ ends 
have been used by different groups (Supplementary Table 1). Systematic comparisons have 
generally demonstrated that longer single gRNAs (containing a longer 3′ portion of the 
tracrRNA sequence) are more active than shorter ones51. The most commonly used single 
gRNA to date is approximately 100 nts in length (Supplementary Table 1) and has been 
shown reliably to direct Cas9 to genomic sites in yeast18, tobacco19, 20, thale cress19, 
rice21, 22, wheat21, sorghum23, mice26, rats26, rabbits27, frog28, fruit flies29, 30, 
roundworms32, silkworm31 and human somatic and pluripotent stem cells13. The tru-gRNAs 
described above are shortened versions of this ~100 nt single gRNA.
Targeting range and choice of gRNA target sites
For gRNAs, the choice of promoter used to express these RNAs can limit the options for 
potential target sites. For example, the RNA polymerase III-dependent U6 promoter or the 
T7 promoter require a G or GG, respectively, at the 5′ end of the RNA to be transcribed 
(Fig. 4a); as a result, standard full-length or tru-gRNAs expressed from these promoters are 
limited to targeting sites that match the forms GN16-19NGG or GGN15-18NGG, sites that 
each occur every 1 in 32 bps or 1 in 128 bps, respectively, in random DNA. Paired nickase 
strategies require the identification of two sites on opposite strands of DNA with an 
appropriate spacing in between (as described above). One strategy to reduce these targeting 
range restrictions is to choose sites without regard to the identities of the first or first two 
bases at the 5′ end (i.e..--making gRNAs that are mismatched at these positions). Another 
potential strategy to bypass these restrictions is to append the required G or GG to the 5′ end 
of the gRNA, thereby encoding gRNA transcripts that are 1 or 2 bps longer (Fig.4b). Both of 
these strategies have been used successfully to produce active gRNAs but with variable 
efficiencies in the genome-editing activities of the Cas9 nucleases47, 54, 57, 62. Larger-scale 
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studies are needed to clarify the effects of using either mismatched or extended gRNAs on 
the efficiencies and specificities of RGN-mediated cleavage. Several groups have provided 
web-based software that facilitates the identification of potential CRISPR RGN target sites 
in user-defined sequences (for example, the ZiFiT Targeter software17, 48 (http://
zifit.partners.org) and the CRISPR Design Tool55 (http://crispr.mit.edu/)).
Delivery of CRISPR-Cas Components
RGNs have been delivered to a broad range of cell types and organisms using a variety of 
delivery methods. In cultured mammalian cells, researchers have used electroporation61, 
Nucleofection13, 50 and Lipofectamine-mediated transfection13, 14, 50 of non-replicating 
plasmid DNA to transiently express Cas9 and gRNAs. Lentiviral vectors have also been 
used to constitutively express Cas9 and/or gRNAs in cultured human 38, 39 and mouse40 
cells. In vitro transcribed RNAs and/or plasmid DNA have been injected directly into 
embryos; for example, in embryos of zebrafish17, fruit flies29, 30, 63, mice24, 26 and rats26. 
Both plasmid DNA and RNA have also been injected into the gonads of adult 
roundworms32, 64-68 and in one study purified Cas9 protein complexed with gRNA was 
injected69. In addition to animal models and cell lines, Cas9 has been used successfully in 
multiple plant species including wheat, rice, sorghum, tobacco, and thale cress using a range 
of standard delivery methods including PEG-mediated transformation of protoplasts, 
Agrobacterium-mediated transfer in embryos and leaf tissue, and/or bombardment of callus 
cells with plasmid DNA19-21, 23. For most RGN applications, transient expression of gRNAs 
and Cas9 is typically sufficient to induce efficient genome editing. Although constitutive 
expression of RGN components might potentially lead to higher on-target editing 
efficiencies, extended persistence of these components in the cell might also lead to 
increased frequencies of off-target mutations, a phenomenon that has been previously 
reported with ZFNs70.
Strategies to experimentally control for RGN off-target effects
The existence of CRISPR RGN-induced off-target effects and our inability to 
comprehensively identify all of these alterations on a genome-wide scale requires 
investigators for now to account for potentially confounding effects of these undesired 
mutations. Several strategies might be used to rule out off-target mutations as a potential 
alternative explanation for any phenotypes observed. For example, complementation with 
re-introduction of a wild-type gene can be used to confirm the effects of knockout 
mutations. In addition, similar to the strategy of targeting a gene with multiple RNAi 
hairpins, one could easily create mutations in the same gene using gRNAs targeted to 
different sites. Presumably, each gRNA will be expected to have a different range of off-
target effects and therefore if the phenotype is observed with each of these different gRNAs 
it would seem unlikely that undesired mutations are the cause. The ease with which multiple 
gRNAs can be rapidly designed and constructed makes it simple and feasible to implement 
this latter type of strategy with the Cas9 system. The high efficacy of the Cas9 nuclease for 
inducing mutations makes it an attractive choice for creating mutant cell lines and whole 
organisms in spite of the need to account for off-target effects.
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Non-nuclease applications of CRISPR-Cas systems
Beyond enabling facile and efficient targeted genome editing, the CRISPR-Cas system has 
the potential to be used to regulate endogenous gene expression or to label specific 
chromosomal loci in living cells or organisms. Catalytically inactive or “dead” Cas9 
(dCas9), a variant bearing both the D10A and H840A mutations that does not cleave DNA, 
can be recruited by gRNAs to specific target DNA sites7, 12(Fig. 3e). Targeting of dCas9 to 
promoters was initially shown to enable repression of gene expression in both Escherichia 
coli71 and human cells72. Interestingly, dCas9 repressed a bacterial promoter efficiently 
when recruited with gRNAs that interacted with either strand of sequences located upstream 
of the promoter; however, when targeting sites downstream of the transcription start point, 
only gRNAs that interacted with the non-template strand induced dCas9-mediated 
repression71. dCas9 also provides a general platform for recruitment of heterologous effector 
domains to specific genomic loci (Fig. 3f). For example, dCas9 fusions to a transcriptional 
activation domain (VP64 or the p65 subunit of nuclear factor kappa B; NF-κB) or a 
transcriptional repression domain (the Krüppel associated box (KRAB) domain) have been 
shown to regulate the expression of endogenous genes in human73-75 and mouse cells76 as 
well as in bacteria71. Changes in gene expression induced by these dCas9 fusions in human 
cells thus far appear to be generally lower than those induced by similar TALE-based 
transcription factors49, 77-80. However, multiplex recruitment of dCas9-based activators 
using between 2 and 10 sgRNAs targeted to the same promoter can result in substantially 
higher levels of human gene activation, presumably due to the phenomenon of activator 
synergy49, 73, 74, 76. This capability of dCas9-based activators to function synergistically is 
consistent with previous observations for TALE-based activators77, 78 in human cells. It will 
be interesting to see in future experiments whether dCas9 fusions to histone modifiers and 
TET proteins can also be used to perform targeted “epigenome editing” including the 
alteration of specific histone modifications and demethylation of particular cytosine bases in 
human cells, as has been recently described with TAL effector DNA-binding 
domains75, 81, 82.
An alternative strategy for tethering heterologous effector domains to DNA-bound dCas9-
gRNA complexes is to exploit well-defined RNA–protein interaction pairs. This approach 
uses two engineered components: a gRNA that has one or two RNA binding sites for the 
phage MS2 coat protein fused to its 3′ end; and a fusion of MS2 coat protein to an effector 
domain49. Addition of the MS2 RNA binding sequences to the gRNA does not abolish its 
ability to target dCas9 to specific DNA sites. Furthermore, co-expression of the MS2 coat 
protein fusion with the hybrid gRNA and dCas9 has been used to recruit activation domains 
to a gene promoter in human cells49. Although the activation observed appears to be 
somewhat less robust than direct fusions to dCas9, this type of configuration might provide 
additional options and flexibility for multiplex recruitment of effector domains to a specific 
promoter. For example, one can imagine leveraging multiple gRNAs and MS2 coat protein 
binding sites on each of gRNA to recruit many copies of different domains to the same 
promoter.
Thus far, evidence suggests that the effects of the small number of dCas9-activation domain 
or dCas9-repression domain fusions tested to date can be highly specific in human cells as 
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judged by RNA-seq experiments76, 83; however, this may be because not all binding events 
lead to changes in gene transcription. It remains to be determined whether the effects of 
other dCas9 fusions prove to be as specific in their genome-wide effects as these dCas9-
based activators and repressors or if, like their nuclease counterparts, they will benefit from 
enhanced specificity conferred by tru-gRNAs.
In yet another application, it has been demonstrated that an EGFP-dCas9 fusion can be used 
to visualize DNA loci harboring repetitive sequences such as telomeres with just a single 
gRNA or non-repetitive loci using 26 to 36 gRNAs tiled across a 5 kb region of DNA84. 
This imaging strategy provides a powerful tool for studying chromosome dynamics and 
structure and extends the dCas9 system beyond gene expression-based applications.
Future directions
Progress in the development of Cas9-based technologies over the past eighteen months has 
been stunning to watch but many interesting questions and applications remain yet to be 
addressed and explored.
First, methods for expanding the targeting range of RNA-guided Cas9 will be important for 
inducing precise HDR or NHEJ events as well as for implementing the paired nickase and 
other multiplex strategies. As noted above, a major source of this targeting range restriction 
for Cas9, paired Cas9 nickases, and dCas9 fusions is the need for a PAM sequence matching 
the form NGG. The ability to exploit alternative PAM sequences of the form NAG or 
NNGG has been noted7, 8, 51 but more experiments are needed to ascertain how robustly 
these sequences are actually recognized and cleaved. Other gRNA-Cas9 platforms with 
different PAM sequences isolated from Streptococcus thermophilus, Neisseria meningitidis, 
and Treponema denticola have also been characterized10, 11, 14 and identification of more of 
these systems from other species85 could further enhance the targeting range of the platform.
Second, the field urgently needs to develop unbiased strategies to globally assess the off-
target effects of Cas9 nucleases or paired nickases in any genome of interest. Such methods 
will be crucial for evaluating how effectively improvements described to date actually 
enhance the specificity of the platform. In addition, although tru-gRNAs and paired nickases 
can reduce off-target effects, it is possible that further improvements will be needed, 
especially for therapeutic applications. Ideally, these new strategies could be combined with 
existing approaches, such as the paired nickases and tru-gRNAs. Examples of such 
improvements might involve using protein engineering to modify Cas9 and/or modifying the 
nucleotides used by the gRNA to mediate recognition of the target DNA site. Alternatively, 
the construction of inducible forms of Cas9 and/or gRNAs might provide a means to 
regulate the active concentration of these reagents in the cell and thereby improve the ratio 
of on- and off-target effects.
Third, methods for efficient delivery and expression of CRISPR-Cas system components 
will undoubtedly need to be optimized for each particular cell-type or organism to be 
modified. For example, some cell types might be refractory to transfection and/or infection 
by standard viral vectors. A related challenge will be to develop methods that enable tissue-
specific, cell-type-specific or developmental stage-specific expression of either the gRNAs 
Sander and Joung Page 10
Nat Biotechnol. Author manuscript; available in PMC 2014 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
and/or the Cas9 nuclease. Strategies that enable efficient multiplex expression of large 
numbers of gRNAs simultaneously from one vector will also enable this advantage of the 
technology to be leveraged. Collectively, these advances will be important for research use 
and therapeutic applications.
Lastly, strategies for shifting the balance away from NHEJ-mediated indel mutations and 
towards HDR-driven alterations remain a priority for development. Although high rates of 
HDR can be achieved with the CRISPR RGNs and single-stranded DNA oligonucleotides, 
competing mutagenic NHEJ also occurs simultaneously. This limitation is particularly 
problematic when using HDR to induce point mutation changes (as opposed to insertions) in 
the protospacer part of the target site; these successfully types of altered alleles can still be 
efficiently re-cut and then mutagenized by NHEJ, thereby reducing the yield of correctly 
edited sequences. One of the challenges with developing an approach to improve the 
HDR:NHEJ ratio is that inhibition of NHEJ is likely to be poorly tolerated by most cells, 
given its central role in normal DNA repair. For therapeutic applications seeking to exploit 
HDR in particular, reduction or elimination competing NHEJ will be a critically important 
requirement.
The simplicity, high efficiency and broad applicability of the RNA-guided Cas9 system have 
positioned this technology to transform biological and biomedical research. The ease with 
which researchers can now make changes in the sequence or expression of any gene will 
enable reverse genetics to be performed in virtually any organism or cell type of interest. In 
addition, the capability to construct large libraries of gRNAs for altering or regulating genes 
of interest will enable facile comprehensive forward genetic screens. All of these systems 
can also be multiplexed by expressing multiple gRNAs in a single cell, thereby further 
extending the complexity of forward and reverse genetic experiments that can be performed. 
Although the off-target effects of Cas9 remain to be defined on a genome-wide scale, much 
progress has already been made toward improving specificity and further advances will 
undoubtedly come rapidly given the intensity of research efforts in this area. All of these 
recent and future advances in developing and optimizing Cas9-based systems for genome 
and epigenome editing should propel the technology forward to therapeutic applications, 
opening the door to treating a wide variety of human diseases.
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Box 1
Meganucleases, ZFNs and TALENs
Meganucleases, ZFNs, and TALENs have been utilized extensively for genome editing 
in a variety of different cell types and organisms. Meganucleases are engineered versions 
of naturally occurring restriction enzymes that typically have extended DNA recognition 
sequences. Zinc finger nucleases (ZFNs) and Transcription Activator-Like Effector 
Nucleases (TALENs) are artificial fusion proteins composed of an engineered DNA 
binding domain fused to a non-specific nuclease domain from the FokI restriction 
enzyme. Zinc finger and transcription activator-like effector repeat domains with 
customized specificities can be joined together into arrays capable of binding to extended 
DNA sequences.
The engineering of meganucleases has been challenging for most academic researchers 
because the DNA recognition and cleavage functions of these enzymes are intertwined in 
a single domain86, 87. By contrast, the DNA binding domains of ZFNs and TALENs are 
distinct from the FokI cleavage domain88, thereby making it more straightforward to 
modify the DNA-binding specificities of these nucleases. However, robust construction 
of engineered zinc finger arrays has also proven to be difficult for many laboratories due 
to the need to account for context-dependent effects between individual finger domains in 
an array89. Despite the availability of various publicly available methods designed to 
simplify the challenge of creating ZFNs90-96, these nucleases have not been engineered 
by a wide range of laboratories. In contrast to zinc fingers, TALE repeat domains appear 
to be less affected by context-dependence and can be robustly assembled in a modular 
fashion to recognize virtually any DNA sequence97 using a simple one-to-one code 
between individual repeats and the four possible DNA nucleotides98, 99. Although much 
simpler to design than meganucleases or ZFNs, the assembly of DNAs encoding large 
numbers of highly conserved TALE repeats can require the use of non-standard 
molecular biology cloning methods. Many user-friendly methods for making such 
assemblies have been described in the literature100 but the highly repetitive nature of 
TALEN-coding sequences also creates barriers to their delivery using certain viral 
vectors, such as lentiviruses101. Nonetheless, the greater simplicity of TALENs relative 
to meganucleases and ZFNs has led to their adoption over the past several years by a 
broader range of scientists. The question of whether to utilize these platforms for a given 
application must be answered on a case-by-case basis and we refer the reader to recent 
reviews on these different technologies for additional information86, 88, 100.
Sander and Joung Page 17
Nat Biotechnol. Author manuscript; available in PMC 2014 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. Nuclease-induced genome editing
Nuclease induced double-strand breaks (DSBs) can be repaired by NHEJ or HDR pathways. 
Imprecise NHEJ-mediated repair can produce variable-length insertion and deletion 
mutations at the site of the DSB. HDR-mediated repair can introduce precise point 
mutations or insertions from a single-stranded or double-stranded DNA donor template.
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Figure 2. Naturally occurring and engineered CRISPR-Cas9 systems
(a) Naturally occurring CRISPR-Cas systems incorporate foreign DNA sequences into 
CRISPR arrays, which then produce crRNAs bearing “protospacer” regions that are 
complementary to the foreign DNA site. crRNAs hybridize to tracrRNAs (also encoded by 
the CRISPR system) and this pair of RNAs associates with the Cas9 nuclease. crRNA/
tracrRNA/Cas9 complexes recognize and cleave foreign DNAs bearing the protospacer 
sequences. Additional details in the text. (b) and (c) Engineered CRISPR-Cas system 
consists of a fusion between a crRNA and part of the tracrRNA sequence. This single gRNA 
then complexes with Cas9 to mediate cleavage of target DNA sites that are complementary 
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to the first (5′) 20 nts of the gRNA and that lie next to a PAM sequence. Additional details 
in the text.
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Figure 3. Cas9-based systems for altering gene sequence or expression
(a) Cas9 nuclease creates double strand breaks at DNA target sites with complementarity to 
the 5′ end of a gRNA. (b) Cas9 nickase created by mutation of the RuvC nuclease domain 
with a D10A mutation. This nickase cleaves only the DNA strand that is complementary to 
and recognized by the gRNA. (c) Cas9 nickase created by mutation of the HNH nuclease 
domain with a H840A mutation. This nickase cleaves only the DNA strand that does not 
interact with the sRNA. (d) Paired nickase strategy for improving Cas9 specificity. D10A 
Cas9 nickase directed by a pair of appropriately oriented gRNAs leads to induction of two 
nicks that, if introduced simultaneously, would be expected to generate a 5′ overhang. (e) 
Catalytically inactive or ‘dead’ Cas9 (dCas9) that can be recruited by a gRNA without 
cleaving the target DNA site. (f) Catalytically inactive dCas9 bearing dual D10A/H840A 
mutations fused to a heterologous effector domain.
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Figure 4. Limitations on targeting range of guide RNAs
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(a) Potential target sites of gRNAs expressed from a U6 promoter. Restrictions are imposed 
by the requirement for a G at the first 5′ nucleotide of the gRNA and by the need for an 
NGG adjacent to the target site (top). One strategy to work around the requirement for a 5′ G 
is to append this nucleotide to the beginning of the gRNA (bottom). (b) Potential target sites 
of gRNAs expressed from a T7 promoter. Restrictions are imposed by the requirement for a 
GG at the first two nucleotides of the gRNA and by the need for an NGG adjacent to the 
target site (top). One strategy to work around the requirement for a 5′ GG dinucleotide is to 
append GG to the beginning of the gRNA (bottom).
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Table 1
Published examples of cell types and organisms modified by Cas9
Cell type or organism Cas9 form Cell type Reference numbers
Human cells
Cas9 nuclease
HEK293FT, HEK293T,
HEK293, K562, iPSC,
HUES9, HUES1, BJ-
RiPS ,HeLa, Jurkat,
U2OS
13-16, 47, 49-51, 54, 58,
61, 72, 83, 102, 103
Cas9 nickase HEK293FT, HEK293T 13, 14, 47, 49
dCas9 (gene regulation) HEK293FT, HEK293T 72-74, 76, 83
dCas9 (imaging) HEK293T, UMUC3,HeLa 84
Mouse or mouse cells
Cas9 nuclease embryos 14, 24-26
Cas9 nickase embryos 47
dCas9 (gene regulation) NIH3T3 76
Rat Cas9 nuclease embryos 26, 36
Rabbit Cas9 nuclease embryos 27
Frog Cas9 nuclease embryos 28
Zebrafish Cas9 nuclease embryos 17, 33, 37, 62, 103
Fruit fly Cas9 nuclease embryos 29, 30, 63
Silkworm Cas9 nuclease embryos 31
Roundworm Cas9 nuclease adult gonads 32, 64-69
Rice Cas9 nuclease protoplasts,
callus cells 21, 23
Wheat Cas9 nuclease protoplasts 21
Sorghum Cas9 nuclease embryos 23
Tobacco Cas9 nuclease protoplasts,leaf tissue 19, 20, 23
Thale cress Cas9 nuclease protoplasts,
seedlings 19, 23
Yeast Cas9 nuclease S. cerevisiae 18
Bacteria
Cas9 nuclease S. pneumonia,E. coli 8
dCas9 (gene regulation) E. coli 71, 72
Human Embryonic Kidney (HEK); Induced Pluripotent Stem Cells (iPSCs);
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